

EASTERNMED FUNDS VCIC PLC  
INTERIM FINANCIAL STATEMENTS  
FOR THE SIX MONTHS ENDED 30 JUNE 2022

# EASTERNMED FUNDS VCIC PLC

---

## INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

### CONTENTS

### PAGE

Board of Directors and other officers	1
Unaudited statement of profit or loss and other comprehensive income	2
Unaudited statement of financial position	3
Unaudited statement of net assets attributable to holders of investor shares	4
Unaudited statement of cash flows	5
Notes to the unaudited financial statements	6 - 15

# EASTERNMED FUNDS VCIC PLC

---

## BOARD OF DIRECTORS AND OTHER OFFICERS

**Board of Directors:**

Athanasios J. Martinos  
Andreas Theophanous  
Ioannis Papaioannou  
Stavros A. Karides  
Maria Panayi Drakos

**Secretary:**

K and K Secretarial Limited  
11 Kyriakou Matsi Street, Nikis Center, 8th floor  
1082 Nicosia  
Cyprus

**Management Company:**

Easternmed Asset Management Services Ltd  
11 Kyriakou Matsi Street, Nikis Center, 8th floor  
1082 Nicosia  
Cyprus

**Fund Administration:**

MFO Asset Management Ltd  
66 Acropolis Avenue, Acropolis Tower, 1st floor  
2012 Nicosia  
Cyprus

**External Auditors:**

KPMG Limited  
14 Esperidon Street  
1087 Nicosia  
Cyprus

**External Legal Advisers:**

Karides & Karides LLC  
11 Kyriakou Matsi Street, Nikis Center, 8th floor  
1082 Nicosia  
Cyprus

**Registered office:**

48 Themistokli Dervi Avenue  
Athienitis Centennial Building, Office 104  
1066 Nicosia  
Cyprus

**Depository:**

Bank of Cyprus Public Company Ltd  
51 Stasinou Street  
1398 Nicosia  
Cyprus

**Registration number:**

HE354779

# EASTERNMED FUNDS VCIC PLC

## UNAUDITED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE SIX MONTHS ENDED 30 JUNE 2022

	Note	Easternmed Equities Fund Class A 30 June 2022 €	Easternmed Equities Fund Class A 30 June 2021 €
<b>Revenue</b>			
Dividend income		<b>9.599.015</b>	6.955.099
Interest income	6	<b>96.475</b>	72.387
Net realised gains on financial assets at fair value through profit or loss	8	<b>8.728</b>	205.716
Net unrealised (losses)/gains on financial assets at fair value through profit or loss	7	<b>(14.561.519)</b>	32.250.732
Net foreign currency gains		<b>320.995</b>	30.082
Other operating income		<b>21.416</b>	22.333
<b>Total revenue</b>		<b>(4.514.890)</b>	<b>39.536.349</b>
<b>Operating expenses</b>			
Management fees		<b>(264.404)</b>	(380.185)
Depositary fees		<b>(78.506)</b>	(65.761)
Administration fees		<b>(24.795)</b>	(24.795)
Directors' fees		<b>(4.785)</b>	(4.785)
Transaction costs		<b>(53.121)</b>	(49.001)
Auditors' remuneration		<b>(4.611)</b>	(4.611)
Secretarial fees		<b>(2.380)</b>	(2.380)
Licences and annual contributions		<b>(900)</b>	(900)
Sundry expenses		<b>(622)</b>	(897)
<b>Total operating expenses</b>		<b>(434.124)</b>	<b>(533.315)</b>
<b>Operating (loss)/profit before finance costs</b>		<b>(4.949.014)</b>	<b>39.003.034</b>
Net finance costs	9	<b>(10.457)</b>	(7.008)
<b>(Decrease)/increase in net assets attributable to holders of investor shares before tax</b>		<b>(4.959.471)</b>	<b>38.996.026</b>
Tax	10	<b>(969.993)</b>	(717.572)
<b>(Decrease)/increase in net assets attributable to holders of investor shares for the period</b>		<b>(5.929.464)</b>	<b>38.278.454</b>


The notes on pages 6 to 15 form an integral part of these financial statements.

# EASTERNMED FUNDS VCIC PLC

## UNAUDITED STATEMENT OF FINANCIAL POSITION AT 30 JUNE 2022

	Note	<b>Easternmed Equities Fund Class A 30 June 2022</b> €	Easternmed Equities Fund Class A 31 December 2021 €
<b>ASSETS</b>			
Financial assets at fair value through profit or loss	12	<b>275.664.125</b>	298.659.989
Cash and cash equivalents	13	<b>10.028.586</b>	3.237.633
Other receivables	11	<b>356.917</b>	104.840
<b>Total assets</b>		<b><u>286.049.628</u></b>	<u>302.002.462</u>
<b>LIABILITIES</b>			
Other payables	15	<b>145.623</b>	114.505
Current tax liabilities	16	<b>2.589</b>	1.557
		<b><u>148.212</u></b>	<u>116.062</u>
<b>Total liabilities (excluding net assets attributable to holders of investor shares)</b>		<b><u>148.212</u></b>	<u>116.062</u>
<b>Net assets attributable to holders of investor shares</b>	14	<b><u>285.901.416</u></b>	<u>301.886.400</u>
		<b><u>285.901.416</u></b>	<u>301.886.400</u>

On 26 August 2022 the Board of Directors of Easternmed Funds VCIC Plc authorised these financial statements for issue.



Athanasios I. Martinos  
Director



Ioannis Papaioannou  
Director

The notes on pages 6 to 15 form an integral part of these financial statements.

# EASTERNMED FUNDS VCIC PLC

## UNAUDITED STATEMENT OF NET ASSETS ATTRIBUTABLE TO HOLDERS OF INVESTOR SHARES FOR THE SIX MONTHS ENDED 30 JUNE 2022

	<b>Easternmed Equities Fund Class A 30 June 2022</b>	Easternmed Equities Fund Class A 30 June 2021
	€	€
Balance at 1 January	<b>301.886.400</b>	222.969.302
(Decrease)/increase in net assets attributable to holders of investor shares	<b>(5.929.464)</b>	38.278.454
<b>Contributions and redemptions by holders of investor shares:</b>		
Subscription for Class A investor shares during the period	-	14.999.713
Redemption for Class A investor shares during the period	<b>(10.055.520)</b>	-
<b>Total contributions and redemptions by holders of investor shares</b>	<b>(10.055.520)</b>	14.999.713
<b>Balance at 30 June</b>	<b>285.901.416</b>	276.247.469

The notes on pages 6 to 15 form an integral part of these financial statements.

# EASTERNMED FUNDS VCIC PLC

## UNAUDITED STATEMENT OF CASH FLOWS FOR THE SIX MONTHS ENDED 30 JUNE 2022

	Note	Easternmed Equities Fund Class A 30 June 2022 €	Easternmed Equities Fund Class A 30 June 2021 €
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
<b>(Decrease)/increase in net assets attributable to holders of investor shares before tax</b>		<b>(4.959.471)</b>	38.996.026
Adjustments for:			
Net unrealised losses/(gains) on financial assets at fair value through profit or loss	7	<b>14.561.519</b>	(32.250.732)
Net realised gains on financial assets at fair value through profit or loss	8	<b>(8.728)</b>	(205.716)
Net foreign currency gains		<b>(320.995)</b>	(30.082)
Dividend income		<b>(9.599.015)</b>	(6.955.099)
Interest income	6	<b>(96.475)</b>	(72.387)
Negative interest on cash and cash equivalent	9	<b>10.123</b>	6.482
		<b>(413.042)</b>	(511.508)
<b>Changes in working capital:</b>			
Decrease in balances due to brokers		-	(1.005.193)
Increase in other payables		<b>31.118</b>	81.199
<b>Cash used in operations</b>		<b>(381.924)</b>	(1.435.502)
Interest received		<b>12.027</b>	32.284
Dividends received		<b>9.346.938</b>	6.955.099
Proceeds from sale of financial assets at fair value through profit or loss		<b>35.501.327</b>	4.226.878
Payments for acquisition of financial assets at fair value through profit or loss		<b>(26.973.806)</b>	(26.669.930)
Tax paid		<b>(1.095)</b>	(3.436)
Withholding tax paid		<b>(967.866)</b>	(716.478)
<b>Net cash generated from/(used in) operating activities</b>		<b>16.535.601</b>	(17.611.085)
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Proceeds from issue of investor shares	14	-	14.999.713
Payments on redemption of investor shares		<b>(10.055.520)</b>	-
Interest paid		<b>(10.123)</b>	(6.482)
<b>Net cash (used in)/generated from financing activities</b>		<b>(10.065.643)</b>	14.993.231
<b>Net increase/(decrease) in cash and cash equivalents</b>		<b>6.469.958</b>	(2.617.854)
Cash and cash equivalents at beginning of the period		<b>3.237.633</b>	5.406.790
Effect of exchange rate fluctuations on cash held		<b>320.995</b>	30.082
<b>Cash and cash equivalents at end of the period</b>	13	<b>10.028.586</b>	2.819.018

The notes on pages 6 to 15 form an integral part of these financial statements.

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

### 1. Incorporation and principal activities

#### Country of incorporation

Easternmed Funds VCIC Plc (the 'Fund') was incorporated in Cyprus on 19 April 2016 as a public limited liability company under the provisions of the Cyprus Companies Law, Cap. 113. The Fund was granted UCITS license No. UCITS 07/78 by the Cyprus Securities and Exchange Commission on 22 March 2016. Its registered office is at 48 Themistokli Dervi Avenue, Athienitis Centennial Building, Office 104, 1066 Nicosia, Cyprus.

The Fund as an umbrella investment company comprises various sub-funds each relating to a separate investment portfolio of securities, cash and other assets. Separate classes of shares are issued in relation to the sub-funds. The Board of Directors of the Fund may authorise the creation of additional sub-funds/share classes in the future subject to CySEC approval. As of 30 June 2022, there was one sub-fund active, namely the Easternmed Equities Fund Class A (the 'Sub-Fund').

The Sub-Fund is primarily involved in investing in a highly diversified portfolio of equity securities issued by companies listed on major European stock exchanges and on the New York Stock Exchange (NYSE), investment funds and corporate debt securities, with the objective of providing shareholders with long-term capital growth subject to moderate volatility.

The Fund's management is performed by Easternmed Asset Management Services Ltd (the 'Management Company'), with the administration delegated to MFO Asset Management Ltd (the 'Fund Administrator').

#### Unaudited financial statements

The financial statements for the six months ended on 30 June 2021 and 2022 respectively, have not been audited by the external auditors of the Company.

### 2. Significant accounting policies

The financial statements, which are presented in Euros, have been prepared in accordance with international Financial Reporting Standards (the 'IFRSs'), including International Accounting Standard 34 "Interim Financial Reporting". These interim financial statements do not include all the information required for the full annual financial statements prepared in accordance with IFRSs.

The accounting policies used in the preparation of the financial statements are in accordance with those used in the annual financial statements for the year ended 31 December 2021.

Costs that are incurred during the financial year are anticipated or deferred for interim reporting purposes if, and only if, it is also appropriate to anticipate or defer that type of cost at the end of the financial year.

Corporation tax is calculated based on the expected tax rates for the whole financial year.

These financial statements must be read in conjunction with the annual financial statements for the year ended 31 December 2021.

### 3. New accounting pronouncements

At the date of approval of these financial statements, standards and interpretations were issued by the International Accounting Standards Board (the 'IASB') which were not yet effective. Some of them were adopted by the European Union (the 'EU') and others not yet. The Board of Directors expects that the adoption of these accounting standards in future periods will not have a material effect on the financial statements of the Fund.



# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

### 4. Critical accounting estimates and judgments

The preparation of financial statements in conformity with IFRSs requires the use of certain critical accounting estimates and requires Management to exercise its judgement in the process of applying the Fund's accounting policies. It also requires the use of assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on Management's best knowledge of current events and actions, actual results may ultimately differ from those estimates.

The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

#### • Fair value of financial assets

The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. The Fund uses its judgment to select a variety of methods and make assumptions that are mainly based on market conditions existing at each reporting date. The fair value of the financial assets available for sale has been estimated based on the fair value of these individual assets.

#### • Income taxes

Significant judgment is required in determining the provision for income taxes. There are transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business. The Fund recognises liabilities for anticipated tax audit issues based on estimates of whether additional taxes will be due. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the period in which such determination is made.

### 5. Fair value measurement

The table below analyses financial instruments carried at fair value, by valuation method. The different levels have been defined as follows:

- Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 - inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3 - inputs for the asset or liability that are not based on observable market data (unobservable inputs).

<b>30 June 2022</b>	Level 1 €	Level 2 €	Level 3 €	Total €
<b>Assets measured at fair value</b>				
<b>Financial assets mandatorily at fair value through profit or loss at inception:</b>				
Equity securities	250.478.564	-	-	250.478.564
Unlisted open-ended investment funds	-	14.659.606	-	14.659.606
Debt securities	10.525.955	-	-	10.525.955
<b>Total</b>	<b>261.004.519</b>	<b>14.659.606</b>	<b>-</b>	<b>275.664.125</b>
31 December 2021	Level 1 €	Level 2 €	Level 3 €	Total €
<b>Assets measured at fair value</b>				
<b>Financial assets mandatorily at fair value through profit or loss at inception:</b>				
Equity securities	277.471.046	-	-	277.471.046
Unlisted open-ended investment funds	-	14.704.804	-	14.704.804
	6.484.139	-	-	6.484.139
<b>Total</b>	<b>283.955.185</b>	<b>14.704.804</b>	<b>-</b>	<b>298.659.989</b>

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

### 5. Fair value measurement (continued)

Valuation techniques and the inputs used for the fair value measurements categorised within Level 2 of the fair value hierarchy is given below:

#### Corporate debt securities

Where quoted prices in an active market are available at the measurement date for an identical corporate debt security, those prices are used (Level 1 measurement). The Fund measures instruments quoted in an active market at bid price.

#### Listed equity securities

Listed equity securities are valued using quoted prices in an active market for an identical instrument (Level 1 measurement).

#### Unlisted open-ended investment funds

The Fund invests in open-ended investment funds, that are open to new investors and allow redemptions at net asset value, and are not quoted in an active market. The fair value of investments in the unlisted open-ended investment funds is determined either using unadjusted NAV (Level 2 measurement) or by applying a discount to the NAV (Level 3 measurement). The unadjusted NAV is used when the units in a fund are redeemable at the reportable NAV at, or approximately at, the measurement date. If this is not the case, then NAV is used as a valuation input and an adjustment is applied for lack of marketability and restrictions on redemptions. This adjustment is based on management judgement after considering the period of restrictions and the nature of the underlying investments.

There were no transfers between Level 1 and Level 2 in the period.

### 6. Interest income

Interest income is analysed as follows:

	<b>Easternmed Equities Fund Class A 30 June 2022 €</b>	Easternmed Equities Fund Class A 30 June 2021 €
Cash and cash equivalents	-	30
Listed debt securities at fair value through profit or loss	<b>96.475</b>	72.357
	<b>96.475</b>	<b>72.387</b>

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

### 7. Net unrealised change on financial assets at fair value through profit or loss

Net unrealised gains/(losses) on financial assets at fair value through profit or loss is analysed as follows:

	<b>Easternmed Equities Fund Class A 30 June 2022 €</b>	Easternmed Equities Fund Class A 30 June 2021 €
Equity securities	<b>(9.991.383)</b>	30.928.422
Unlisted open-ended investment funds	<b>(1.903.265)</b>	1.312.650
Debt securities	<b>(2.666.871)</b>	9.660
	<b><u>(14.561.519)</u></b>	<b><u>32.250.732</u></b>

The net unrealised gains/(losses) from financial assets at fair value through profit or loss represents the difference between the carrying amount of a financial instrument at the beginning of the reporting period and its carrying amount at the end of the reporting period.

### 8. Net realised change on financial assets at fair value through profit or loss

Net realised gains/(losses) on financial assets at fair value through profit or loss is analysed as follows:

	<b>Easternmed Equities Fund Class A 30 June 2022 €</b>	Easternmed Equities Fund Class A 30 June 2021 €
Equity securities	<b>404.660</b>	76.937
Unlisted open-ended investment funds	<b>(395.803)</b>	52.252
Debt securities	<b>(130)</b>	76.527
	<b><u>8.727</u></b>	<b><u>205.716</u></b>

The net realised gains/(losses) on financial assets at fair value through profit or loss represents the difference between the carrying amount of a financial asset at the beginning of the reporting period, or the transaction price if it was purchased in the current reporting period, and its settlement price.

### 9. Finance costs

	<b>Easternmed Equities Fund Class A 30 June 2022 €</b>	Easternmed Equities Fund Class A 30 June 2021 €
Negative interest on cash and cash equivalents	<b>10.123</b>	6.482
Sundry finance expenses	<b>334</b>	526
	<b><u>10.457</u></b>	<b><u>7.008</u></b>

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

### 10. Tax

	<b>Easternmed Equities Fund Class A 30 June 2022 €</b>	Easternmed Equities Fund Class A 30 June 2021 €
Corporation tax	<b>2.127</b>	1.094
Withholding tax	<b>967.866</b>	716.478
<b>Charge for the period</b>	<b><u>969.993</u></b>	<b><u>717.572</u></b>

The total charge for the year can be reconciled to the accounting results as follows:

	<b>Easternmed Equities Fund Class A 30 June 2022 €</b>	Easternmed Equities Fund Class A 30 June 2021 €
(Decrease)/increase in net assets attributable to holders of investor shares before tax	<b><u>(4.959.471)</u></b>	<b><u>38.996.026</u></b>
Applicable tax rates	<b>12,50%</b>	12,50%
Tax calculated at the applicable tax rates	<b>(619.934)</b>	4.874.503
Tax effect of expenses not deductible for tax purposes	<b>1.874.337</b>	58.532
Tax effect of allowances and income not subject to tax	<b>(1.252.276)</b>	(4.931.941)
Withholding tax	<b>967.866</b>	716.478
<b>Tax charge</b>	<b><u>969.993</u></b>	<b><u>717.572</u></b>

The Fund is subject to corporation tax on taxable profits at the rate of 12,5%.

Under certain conditions interest income may be subject to defense contribution at the rate of 30%. In such cases this interest will be exempt from corporation tax. In certain cases, dividends received from abroad may be subject to defense contribution at the rate of 17%.

### 11. Other receivables

	<b>Easternmed Equities Fund Class A 30 June 2022 €</b>	Easternmed Equities Fund Class A 31 December 2021 €
Dividend receivable	<b>356.917</b>	104.840
	<b><u>356.917</u></b>	<b><u>104.840</u></b>

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

### 12. Financial assets at fair value through profit or loss

	<b>Easternmed Equities Fund Class A 30 June 2022 €</b>	Easternmed Equities Fund Class A 31 December 2021 €
Balance at 1 January	<b>298.659.989</b>	218.566.342
Additions	<b>26.853.056</b>	39.776.039
Disposals	<b>(35.287.401)</b>	(10.711.072)
Net fair value (losses)/gains	<b>(14.561.519)</b>	51.028.680
<b>Balance at 30 June / 31 December</b>	<b><u>275.664.125</u></b>	<u>298.659.989</u>

Financial assets at fair value through profit or loss are analysed as follows:

	<b>Easternmed Equities Fund Class A 30 June 2022 €</b>	Easternmed Equities Fund Class A 31 December 2021 €
<b>Financial assets at fair value through profit or loss</b>		
Equity securities	<b>250.478.564</b>	277.471.046
Unlisted open-ended investment funds	<b>14.659.606</b>	14.704.804
Debt securities	<b>10.525.955</b>	6.484.139
	<b><u>275.664.125</u></b>	<u>298.659.989</u>

The financial assets at fair value through profit or loss are marketable securities and are valued at market value at the close of business on 30 June by reference to Stock Exchange quoted bid prices or over the counter prices. The fair value estimation of the financial assets at fair value through profit or loss is disclosed in notes 4 and 5.

In the statement of cash flows, financial assets at fair value through profit or loss are presented within the section on operating activities as part of changes in working capital. In the statement of profit or loss and other comprehensive income, changes in fair values of financial assets at fair value through profit or loss are recorded in operating income.

### 13. Cash and cash equivalents

For the purposes of the statement of cash flows, the cash and cash equivalents include the following:

	<b>Easternmed Equities Fund Class A 30 June 2022 €</b>	Easternmed Equities Fund Class A 31 December 2021 €
Cash at bank	<b>10.028.586</b>	3.237.633
	<b><u>10.028.586</u></b>	<u>3.237.633</u>

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

### 13. Cash and cash equivalents (continued)

#### Cash and cash equivalents by currency:

	<b>Easternmed Equities Fund Class A 30 June 2022 €</b>	Easternmed Equities Fund Class A 31 December 2021 €
United States Dollars	<b>5.486.892</b>	321.351
Euro	<b>1.123.732</b>	2.007.462
British Pounds	<b>1.418.240</b>	766.593
Norwegian Krone	<b>151.170</b>	79.743
Swedish Krona	<b>37.255</b>	27.295
Canadian Dollars	<b>82.872</b>	24.784
Swiss Franc	<b>1.700.823</b>	-
Danish Krone	<b>27.602</b>	10.405
	<b><u>10.028.586</u></b>	<b><u>3.237.633</u></b>

### 14. Net assets attributable to holders of investor shares

#### 14.1 Investor shares

The Fund was set up with authorised share capital of 500.000.000 investor shares, no fractions of a share are recognised and each share represents the same percentage holding in the overall assets. The price of each investor share in the Fund, at the time of incorporation, was set at €100, with euro as reference currency.

The initial issued share capital of the Fund is 2.000 investor shares issued at the price of €100 each.

Investor shares are classified into Class A investor shares and Class B investor shares. The rights and obligations of the two share classes are identical, with the exemption of the subscription, redemption and management fee charge.

The Minimum Holding and Minimum Initial Subscription required for Class A investor shares is €800.000 and the Minimum Additional Subscription required for Class A investor shares is €500.000. The Minimum Holding, Minimum Initial Subscription and Minimum Additional Subscription required for Class B investor shares is €5.000. These minimum initial and additional subscription amounts may be reduced or increased, at the discretion of the Fund, whenever the Fund considers it reasonable or appropriate, taking into consideration the diversification of shareholders and other factors and subject to the provisions for amendment to the instruments of incorporation of the Fund.

	<b>Easternmed Equities Fund Class A 30 June 2022 Number of shares</b>	<b>Easternmed Equities Fund Class A 30 June 2022 €</b>	Easternmed Equities Fund Class A 31 December 2021 Number of shares	Easternmed Equities Fund Class A 31 December 2021 €
<b>Issued and fully paid</b>				
Balance at 1 January	<b>2.111.052</b>	<b>301.886.400</b>	1.974.942	222.969.302
(Decrease)/increase in net assets attributable to holders of investor shares	-	<b>(5.929.464)</b>	-	61.917.601
Issue of investor shares during the year	-	-	136.110	16.999.497
Redemption of investor shares during the period	<b>(67.600)</b>	<b>(10.055.520)</b>	-	-
<b>Balance at 30 June / 31 December</b>	<b><u>2.043.452</u></b>	<b><u>285.901.416</u></b>	<b><u>2.111.052</u></b>	<b><u>301.886.400</u></b>

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

### 14. Net assets attributable to holders of investor shares (continued)

The rights attaching to the investor shares are as follows:

- The shares may be redeemed daily at the net asset value per share of the respective class.
- The shares carry a right to receive notice of, attend and vote at general meetings.
- The holders of investor shares are entitled to receive all dividends declared and paid by the Fund. On winding-up, the holders are entitled to a return of capital based on the net asset value per share of their respective classes and if applicable to the class the subscription, and redemption fee.

### 15. Other payables

	<b>Easternmed Equities Fund Class A 30 June 2022 €</b>	Easternmed Equities Fund Class A 31 December 2021 €
Accruals	<b>139.752</b>	109.720
Other creditors	<b>2.353</b>	2.353
Payables to related companies (Note 17.3)	<b>3.518</b>	2.432
	<b><u>145.623</u></b>	<u>114.505</u>

### 16. Current tax liabilities

	<b>Easternmed Equities Fund Class A 30 June 2022 €</b>	Easternmed Equities Fund Class A 31 December 2021 €
Corporation tax	<b>2.589</b>	1.557
	<b><u>2.589</u></b>	<u>1.557</u>

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

### 17. Related party balances and transactions

The related party balances and transactions are as follows:

#### 17.1 Management Company

The Fund has appointed the Management Company to provide management services pursuant to a management agreement dated 9 June 2016. Under the terms of the agreement the Fund pays the investment manager 0,50% per annum for Class A investor shares and 1% per annum for Class B investor shares, currently not active, of the average net asset value of the Fund for the relevant fiscal year, for managing the Fund. The management fee is computed daily on the daily value of the Fund's net assets and is paid by debiting it from the Fund at the end of each month. The management fee includes fees to enable the Management Company to perform its tasks and functions, or to provide services, irrespective of whether those functions is carried out by the Management Company itself or have been outsourced to third parties.

On 20 December 2019, an addendum of the management agreement dated 9 June 2016 was signed. The management fee the Fund pays the investment manager for Class A investor shares decreased to 0,30% from 0,50% with effective date 1 January 2020. The Prospectus has been amended accordingly and the holders of investor shares have been informed via email.

On 30 July 2021, a second addendum of the management agreement dated 9 June 2016 was signed. The management fee the Fund pays the Management Company for Class A investor shares decreased to 0,20% from 0,30% with effective date 1 August 2021. The Prospectus has been amended accordingly and the holders of investor shares have been informed via email.

On 31 March 2022, a third addendum of the management agreement dated 9 June 2016 was signed. The management fee the Fund pays the Management Company for Class A investor shares decreased to 0,15% from 0,20% with effective date 1 April 2022. The Prospectus has been amended accordingly and the holders of investor shares have been informed via email.

The management fees for the six months ended 30 June 2022 totaled €380.185 (30 June 2021: €380.185) and are presented in the statement of comprehensive income. The amount outstanding at the period end is €76.431 (31 December 2021: €50.012) and it is included in accruals in other payables.

At 30 June 2022, 10.000 Class A investor shares were held by the Management Company.

#### 17.2 Directors' remuneration

The directors' fees for the six months ended 30 June 2022 totaled €4.785 (30 June 2021: €4.785) and are presented in the statement of comprehensive income. The amount outstanding at the period end is €2.353 (31 December 2021: €2.353) and it is included in other creditors. Directors' remuneration consisted of only fixed directors' fees.

#### 17.3 Payables to related parties (Note 15)

<u>Name</u>	<u>Nature of transactions</u>	<b>Easternmed</b>	Easternmed
		<b>Equities Fund</b>	Equities Fund
		<b>Class A</b>	Class A
		<b>30 June</b>	31 December
		<b>2022</b>	2021
		€	€
Easternmed Asset Management Services Ltd	Other	<b>3.518</b>	2.432
		<b>3.518</b>	<b>2.432</b>

The payables to related parties were provided interest free, and there was no specified repayment date.



# EASTERNMED FUNDS VCIC PLC

---

## NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

### **18. Other key contracts**

The Fund has appointed the Administrator to provide administrative services pursuant to an administration agreement dated 9 June 2016. Under the terms of the agreement the Fund pays the Administrator 0,05% per annum of the average net asset value of the Fund for the relevant fiscal year, with a floor of €12.500 and a ceiling of €50.000 per annum. The administration fee is computed daily on the daily value of the Fund's net assets and is billed at the end of each month. The administrative fees for the six months ended 30 June 2022 totaled €24.795 (30 June 2021: €24.795) and are presented in the statement of comprehensive income. The amount outstanding at the period end is €8.493 (31 December 2021: €8.629) and it is included in accruals in other payables.

The Fund has appointed the Depositary to provide depositary services pursuant to a depositary agreement dated 9 June 2016. Under the terms of the agreement the Fund pays the depositary 0,05% per annum of the average net value of the Fund's assets held by the Depositary during the relevant fiscal year with a minimum fee of €2.500 per quarter. The Depositary's fee is computed daily on the daily valuation of the net assets held by the Depositary and billed at the end of each quarter. This fee includes Depositary fees which may be payable to third parties who undertake to safeguard all or part of the assets of the Fund on the basis of outsourcing arrangements. The Depositary fees for the six months ended 30 June 2022 totaled €78.506 (30 June 2021: €65.761) and are presented in the statement of comprehensive income. The amount outstanding at the period end is €39.121 (31 December 2021: €38.194) and it is included in accruals in other payables.